Published in Thrombosis on January 11, 2012
Aspirin insensitive thrombophilia: transcript profiling of blood identifies platelet abnormalities and HLA restriction. Gene (2013) 0.84
Aspirin resistance in the acute stages of acute ischemic stroke is associated with the development of new ischemic lesions. PLoS One (2015) 0.77
Aspirin treatment failure: is this a real phenomenon? A review of the aetiology and how to treat it. JRSM Short Rep (2013) 0.75
Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. PLoS One (2015) 0.75
Should All High-Risk Patients Receive Acetylsalicylic Acid 81 mg Daily for Primary Prevention of Cardiovascular Disease? Can J Hosp Pharm (2012) 0.75
Aspirin resistance in coronary heart disease: Current understandings and strategies. J Transl Int Med (2016) 0.75
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol (1971) 37.53
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64
Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A (1975) 10.82
Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol (1971) 7.75
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA (2008) 6.15
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med (2001) 5.96
Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A (1975) 4.92
Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med (2005) 4.57
Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet (1996) 4.21
Prostaglandin endoperoxides. A new concept concerning the mode of action and release of prostaglandins. Proc Natl Acad Sci U S A (1974) 4.10
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ (2009) 3.83
The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest (1968) 3.66
The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest (1975) 3.40
A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J (2007) 3.32
Aging biology and geriatric clinical pharmacology. Pharmacol Rev (2004) 3.23
Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet (2000) 2.69
Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res (1980) 2.68
The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol (1995) 2.56
Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol (2011) 2.50
Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation (1985) 2.46
Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest (1978) 2.40
Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet (2010) 2.32
24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost (2010) 2.15
Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest (1983) 2.13
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". J Am Coll Cardiol (2009) 2.11
Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med (1984) 2.00
Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology (2011) 1.97
Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood (1987) 1.96
The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes (2007) 1.92
Aspirin and the stomach. Ann Intern Med (1986) 1.77
Drug insight: aspirin resistance--fact or fashion? Nat Clin Pract Cardiovasc Med (2007) 1.76
Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2008) 1.53
Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther (2006) 1.40
Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol (2008) 1.33
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol (2001) 1.30
Clinical significance of esterases in man. Clin Pharmacokinet (1985) 1.28
Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J Clin Invest (1983) 1.21
Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost (2007) 1.13
Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. Arterioscler Thromb Vasc Biol (1997) 1.11
Acetylation of prostaglandin H2 synthases by aspirin is inhibited by redox cycling of the peroxidase. Biochem Pharmacol (2007) 1.10
Regulation of carboxylesterase 1 (CES1) in human adipose tissue. Biochem Biophys Res Commun (2009) 1.09
Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol (2005) 1.07
Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke (2006) 1.04
Plasma esterases and inflammation in ageing and frailty. Eur J Clin Pharmacol (2008) 1.02
Effect of obesity on platelet reactivity and response to low-dose aspirin. Prev Cardiol (2010) 1.00
Comparative evaluation of the inhibitory effects of aspirin-like drugs on prostaglandin production by human platelets and synovial tissue. Adv Prostaglandin Thromboxane Res (1976) 0.97
COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J (2009) 0.97
Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Curr Drug Metab (2011) 0.97
Trial of repeated low-dose aspirin in diabetic angiopathy. Blood (1986) 0.96
Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact? Nat Rev Cardiol (2009) 0.94
Increased blood plasma hydrolysis of acetylsalicylic acid in type 2 diabetic patients: a role of plasma esterases. Biochim Biophys Acta (2005) 0.93
Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost (2005) 0.90
Physiologic variables affecting thromboxane B2 production in human whole blood. Thromb Res (1985) 0.90
Relationship between age and plasma esterases. Age Ageing (2001) 0.87
Variability in response to aspirin: do we understand the clinical relevance? J Thromb Haemost (2005) 0.87
Platelet signalling abnormalities in patients with type 2 diabetes mellitus: a review. Blood Cells Mol Dis (2008) 0.87
The role of weight and enteric coating on aspirin response in cardiovascular patients. J Thromb Haemost (2010) 0.86
Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. J Thromb Haemost (2010) 0.85
Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin. J Thromb Haemost (2007) 0.84
Increased GPIIB/IIIA expression and altered DNA-ploidy pattern in megakaryocytes of diabetic BB-rats. Eur J Clin Invest (1992) 0.82
Low-dose aspirin in polycythaemia vera: a pilot study. Gruppo Italiano Studio Policitemia (GISP). Br J Haematol (1997) 0.82
Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol (2011) 0.82
Aspirin resistance: truth or dare. Pharmacol Ther (2006) 0.82
Effect of salicylates on human platelets. Lancet (1968) 0.80
Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. Int J Cardiol (2010) 0.79
Antiplatelet therapy: Clopidogrel-PPI interaction, an ongoing controversy. Nat Rev Cardiol (2011) 0.79
High concomitant use of interacting drugs and low use of gastroprotective drugs among NSAID users in an unselected elderly population: a nationwide register-based study. Drugs Aging (2011) 0.79
Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost (1995) 0.78
Erythrocyte and plasma aspirin esterase. Br J Clin Pharmacol (1981) 0.78
Aspirin inhibits rat megakaryocyte thromboxane synthesis. Prostaglandins (1982) 0.77
Rapid return of cyclo-oxygenase active platelets in dogs after a single oral dose of aspirin. Prostaglandins (1981) 0.76
The variability of platelet response to aspirin and clopidogrel: revisiting the Caprie, Cure, Credo, and Match trials. Proc (Bayl Univ Med Cent) (2005) 0.76
Aspirin resistance testing not ready for "prime time". Heart (2009) 0.76
Primary prevention of cardiovascular events in diabetes: is there a role for aspirin? Nat Clin Pract Cardiovasc Med (2009) 0.76
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood (2012) 1.78
Inhibition of telomerase in the endothelial cells disrupts tumor angiogenesis in glioblastoma xenografts. Int J Cancer (2008) 1.55
Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood (2007) 1.19
Telomerase inhibition impairs tumor growth in glioblastoma xenografts. Neurol Res (2006) 0.99
Establishing tumor cell lines from aggressive telomerase-positive chordomas of the skull base. Technical note. J Neurosurg (2006) 0.97
Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response. FASEB J (2010) 0.93
Expression and activity of cyclooxygenase isoforms in skeletal muscles and myocardium of humans and rodents. J Appl Physiol (1985) (2007) 0.87
Tumorigenic potential of olfactory bulb-derived human adult neural stem cells associates with activation of TERT and NOTCH1. PLoS One (2009) 0.85
Influence of local environment on the differentiation of neural stem cells engrafted onto the injured spinal cord. Neurol Res (2006) 0.84
Distinct expression of cyclooxygenase-1 and -2 in the human thymus. Eur J Immunol (2002) 0.83
Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma. Am J Clin Pathol (2008) 0.80
Abnormal megakaryopoiesis and platelet function in cyclooxygenase-2-deficient mice. Thromb Haemost (2015) 0.80
Personalized medicine, pharmacogenetics, and clopidogrel: unraveling variability of response. Mol Interv (2010) 0.76
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement. Thromb Haemost (2016) 0.75